Xeris Biopharma Holdings annual depreciation and amortization
2020
2021
2022
2023
2024
2025
Xeris Biopharma Holdings Depreciation & Amortization Growth & History (XERS)
Xeris Biopharma Holdings's depreciation and amortization was $1.3M for fiscal 2025.
View full Xeris Biopharma Holdings company overviewXeris Biopharma Holdings annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.3M | $86,000 | +7.01% |
| 2024 | 2024-12-31 | $1.2M | −$260,000 | −17.48% |
| 2023 | 2023-12-31 | $1.5M | $88,000 | +6.29% |
| 2022 | 2022-12-31 | $1.4M | $70,000 | +5.27% |
| 2021 | 2021-12-31 | $1.3M | −$138,000 | −9.41% |
| 2020 | 2020-12-31 | $1.5M | — | — |
Xeris Biopharma Holdings quarterly depreciation and amortization
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $323,000 | −$2,000 | −0.62% |
| Q1 2026 | 2026-03-31 | $337,000 | $22,000 | +6.98% |
| Q4 2025 | 2025-12-31 | $3.2M | — | — |
| Q3 2025 | 2025-09-30 | $338,000 | $31,000 | +10.10% |
| Q2 2025 | 2025-06-30 | $325,000 | $44,000 | +15.66% |
| Q1 2025 | 2025-03-31 | $315,000 | −$11,000 | −3.37% |
| Q3 2024 | 2024-09-30 | $307,000 | −$84,000 | −21.48% |
| Q2 2024 | 2024-06-30 | $281,000 | — | — |
| Q1 2024 | 2024-03-31 | $326,000 | — | — |
| Q3 2023 | 2023-09-30 | $391,000 | $31,000 | +8.61% |
| Q3 2022 | 2022-09-30 | $360,000 | $37,000 | +11.46% |
| Q2 2022 | 2022-06-30 | $352,000 | $32,000 | +10.00% |
| Q1 2022 | 2022-03-31 | $321,000 | −$16,000 | −4.75% |
| Q3 2021 | 2021-09-30 | $323,000 | — | — |
| Q2 2021 | 2021-06-30 | $320,000 | — | — |
| Q1 2021 | 2021-03-31 | $337,000 | — | — |
Xeris Biopharma Holdings depreciation and amortization trends
Over the last five fiscal years, Xeris Biopharma Holdings's depreciation and amortization decreased from $1.5M to $1.3M, a change of −$154,000. The latest reported quarter, Q2 2026, shows $323,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Xeris Biopharma Holdings source filings ↗